Table 3 Late-stage anti-amyloid agents: phase 3 dosing regimens and pharmacokinetic profiles
Agent | Dose per visit and total dose* | Route of administration, frequency, and dosing facility | Plasma half-life | Brain penetration | Time to peak brain steady state exposure** |
|---|---|---|---|---|---|
Aducanumab Biogen | 10 mg/kg IV 600–750 mg per month | IV infusion, monthly Titration over 6 months Infusion center | 21 days | < 1.5% | ~ 5 months |
Gantenerumab Roche | 1200 mg SC 1200 mg per month | SC injection, monthly Titration over 6 to 10 months Clinic | 22 days | ~ 1% | ~ 5 months |
BAN2401 Eisai | 10 mg/kg IV 1200–1500 mg per month | IV infusion, twice per month No titration Infusion center | 5.3 days | ~ 0.5% | ~ 2.5 months |
ALZ-801 Alzheon | 265 mg orally 530 mg daily | Oral tablet, twice daily Titration over 2 weeks Home | 36 h | ~ 40% | ~ 1 week |